Yi retweeted
🧬 The IRA’s Orphan Drug Blunder
The IRA was a flawed bill in many ways, but its worst feature may be how it punishes rare disease patients in the name of savings.
It technically exempts orphan drugs from Medicare price controls, but only if they treat a single rare disease. Approve a second indication, and the exemption vanishes.
So companies face a brutal choice: “If an experimental medicine works for two rare diseases, companies might have to jettison one use lest their drug become subject to price controls and return on its investment collapse.”
📉 The damage is already visible
A National Pharmaceutical Council analysis found the % of orphan drugs receiving a second designation fell by half post-IRA (12.1% → 6.3%). Several companies have already canceled studies.
And all because “many diseases share an underlying pathology such as a gene mutation” which makes a single drug potentially useful across multiple indications. That’s exactly the kind of efficiency we should reward. Instead, we penalize it.
💰 The same lawmakers who tout “innovation” now balk at the $5B cost of a fix. But if you believe innovation matters, this shouldn’t even be a debate.
To be blunt:
This is policy designed by people who don’t understand drug development.
“The orphan drug is a microcosm of the IRA’s disincentives to innovate.” And unless this fix passes, patients with rare diseases will keep paying the price.
wsj.com/opinion/orphan-drugs…
🎙️ The BowTiedBiotech Podcast | Ep. 713
IRA Side Effects: Biotech’s Small Molecule Squeeze
The “Pill Penalty” and the Inflation Reduction Act
This week, we break down one of the most disruptive forces reshaping biotech pipelines: the Inflation Reduction Act. Everyone’s talking about cost control, but few are unpacking the deeper consequences for innovation. We are.
💊 What’s inside this episode:
🔹 Why the IRA’s 9-year negotiation window punishes pills but protects injectables
🔹 How the orphan drug carve-out is narrower than you think
🔹 What this means for small molecule R&D and therapeutic access
🔹 The hidden policy levers that could fix it—if anyone’s listening
If you’re a founder navigating pipeline decisions, an investor recalibrating value, or just trying to figure out why everyone’s suddenly allergic to pills, this episode is for you.
bowtiedbiotech.substack.com/…
📣🎙️ TODAY’S PODCAST:
[ 0:00 ] Introduction
[ 0:33 ] Inflation Reduction Act
[ 1:11 ] Pill penalty
[ 2:46 ] Orphan drugs
[ 4:42 ] Unintended consequences
[ 6:00 ] Targeted policy reform
[ 7:22 ] Framing the issue
[ 7:52 ] Balancing affordability & innovation
Yi retweeted
Friendly reminder that you should consider using Boltz-1/Boltz-2 instead of AlphaFold3 to do your research. Boltz models are MIT licensed, that means that you have permission for:
- Commercial use
- Modification
- Distribution
- Private use
min 1:54:30
ebi.ac.uk/training/materials…
Yi retweeted
Got an email from my PhD student today—she had traveled to Tehran just a few weeks ago, right before war was unfolding.
No complaints. No requests. Just a quiet, steady project update—sent with the kind of calm strength that left me speechless.
I sat there staring at the screen, heart full.
Praying for her safety. Praying for peace. ❤️
Yi retweeted
🚀 Xaira Therapeutics has just dropped a game-changer for AI-driven biology.
Today, we unveiled X-Atlas/Orion, the largest publicly available genome-wide Perturb-seq dataset to date—spanning 8.4 million single cells with perturbations across all ~20,000 human protein-coding genes.
This release is not just about scale—it’s about enabling a new era of causal, mechanistic foundation models for biology.
📝 Preprint on bioRxiv: biorxiv.org/content/10.1101/…
📂 Dataset on Figshare:
doi.org/10.25452/figshare.pl…
🔍 What makes X-Atlas/Orion special:
📈 Unprecedented scale & quality: Each cell profiled with deep (~16k UMIs) transcriptomics and rich metadata
🧪 Quantitative dose-response modeling: Thanks to high-fidelity sgRNA detection and ~4 guides per gene, allowing continuous modeling of genetic effects
🧬 FiCS platform: A fully industrialized single-cell perturbation system enabling rapid, reproducible experiments at massive throughput
🧠 This isn’t just “data.” It’s the biological substrate for building virtual cell models that can generalize, predict, and ultimately power AI-native drug discovery.
💬 My final take:
This is a foundational moment for the field. The ability to model how genes affect cell state—quantitatively, causally, and at scale—is what we need to unlock predictive biology.
Kudos to the incredible team at Xaira for open-sourcing this resource so the entire community can build on it.
#PerturbSeq #SingleCell #Genomics #VirtualCell #FoundationModels #AIForBiology #Xaira #DrugDiscovery #SyntheticBiology #CausalAI
More press release: Press release :
🔗 GEN article : genengnews.com/topics/artifi…
🔗 BusinessWire: businesswire.com/news/home/2…
Yi retweeted
My god. PubMed is down.
This might not seem like a big deal against the backdrop of the appalling Ukraine situation, but gutting US biomedical research could ultimately be as or more deadly.

ALT Hmm. We’re having trouble finding that site. We can’t connect to the server at pubmed.ncbi.nlm.nih.gov. If you entered the right address, you can: • Try again later • Check your network connection • Check that Firefox has permission to access the web (you might be connected but behind a firewall) Button: Try again
Yi retweeted
Understanding human biology across scales - from molecules to cells to entire organisms - remains one of biomedicine's greatest challenges in the fight against disease.
Today, we are announcing Phenformer - a multi-scale genetic language model that learns to read and interpret human genomes by connecting DNA, cell and tissue context, molecules and clinical outcomes.
Phenformer is a generative model of molecular mechanisms that enables researchers to unravel the mysteries underlying disease, and could thereby accelerate the development of precise future therapeutics.
Yi retweeted
On Christmas, 2024, the $MIRA token went viral thanks to @waddles_eth sending @blader half the supply. And the rest is history
Now we'll be building community software to help achieve the project's vision:
miradao.gitbook.io/miradao-w…
app.realms.today/dao/3cJYGYU…
ipfs.io/ipfs/bafybeigmfs3y2f…
Hi @blader,
I'm the person who sent you 50% of $MIRA earlier today.
When I saw the story about Mira and her illness, I thought it would be good to buy and send supply to you with the hopes of getting the SOL community behind a good cause on Christmas. I'm really glad that it worked out the way that it has and I hope that the money helps to find a cure both for Mira and anyone else with her condition.
Wishing you and your family a wonderful Christmas.
God Bless,
Waddles
Crypto people don’t read at all
16 mins of @blader talking about his crypto experience:
- $1mn liquid to charity vs $250K gofundme
- paid $150k out of pocket to ppl who lost money on his test coin "zero"
- started liquidity pairs to donate fees vs "dumping"
- crypto ppl don't read, ruined his holiday
Yi retweeted
Really enjoyed sharing the $MIRA story with Sam and Shaan.
New Episode! "Silicon Valley OG shares crazy stories from Zynga early days + 3 business ideas"
Episode 678: Sam Parr ( teapaw.org/theSamParr ) and Shaan Puri ( teapaw.org/ShaanVP ) talk to Siq…
Player links & show notes: mfmpod.com/e/13917051178422/
The most important project of any AI company.
OpenAI's Health AI team is now hiring backend/fullstack SWEs towards our mission of universalizing access to health information!
Please apply if you:
- Can write maintainable, high-quality backend / fullstack code at high velocity
- Are willing to run through walls towards this mission
- Bonus (not required): background building systems that meet the demands of healthcare
Apply here: openai.com/careers/software-…
PS: we're still hiring Research Scientists as well: openai.com/careers/research-…
If you're unsure whether to apply, please do. Hiring talented people is our main bottleneck right now!
7
413
Yi retweeted
Hi folks, here's some updates from this week:
1. As I mentioned before, I met with Paul from @BioDAOxyz and @eperlste from @endrarediseases DAO this week, and we are all excited to partner together to push forward rare disease research. We are exploring doing a token swap and airdrop / claim of $MIRA for $CURES and vice versa. This way, with $CURES in our DAO, any promotion I will do for rare disease causes on behalf of $CURES will also accrue value to $MIRA through our treasury.
2. @The_Delysium / $AGI's team has fully confirmed their participation to this project. It will start lightly with two team members helping our part time for community management and updates. Their own resources unfortunately are also very constrained in this bear market, but they will do their best to help support us as well. Expect to see them (Ellen and Chandler) say hello here in the next few days.
3. I recorded a 2 hour long podcast about $MIRA and our mission with @tyinlife who runs community at Delysium. I will update the community and promote it when it is live. I have also been invited to their annual conference and will attend virtually where I will talk about $MIRA and how to raise money from investors to some of the most influential people in crypto.
4. We had a private update call with Hankinson Lab - they are very thankful for $MIRA's contribution to the lab. We still have plans to do a spaces, but unfortunately @Tchankinson recently has had a heavy load of surgical work and that has been delayed.
5. Unfortunately, Mira's tumor has continued to grow and I am spending more time finding new options for her and studying. The silver lining for this community is that I am working with @ayushnoori from Harvard University who has reached out to volunteer time and technology to help validate their own AI drug foundational models and help find new drug targets for Mira and other patients. We also have a call scheduled with MD Anderson about potentially funding new personalized vaccines treatments - there is currently about $50K in my charity wallet in SOL that we may use for donation purposes, but I am mindful that $MIRA has gone down significantly and until the price recovers, our ability to donate to more causes and create more attention is limited.
6. I am very aware that $MIRA's price has gone down significantly. I have the same incentive as everyone else to raise the prices, because if it does not, then our ability to donate to more rare disease causes goes to zero, which is not what I want. I am grateful to everyone who is still here, and I genuinely feel very sad that so many people in the community are carrying large losses as a result of $MIRA, especially because I know a lot of folks here don't have that much money and even a hundred dollars in losses means a lot. I feel a large responsibility to do the best I can for the community, but the realities of running a day job and trying to find a good treatment for my daughter has made my ability to make an impact unfortunately limited, for which I am very sorry to you all. I am still here and will continue to push for the long term.
Hope in action. 💙 The $MIRA and @0xMiraDAO community supported @blader and came together to honor Mira and advance rare brain tumor research at @ChildrensColo. More than $1 million was donated to support Dr. Todd Hankinson’s research. Read more: givechildrensco.org/mira
Yi retweeted
We are working on some exciting projects. We have a research team composed of PhDs and clinicians conducting research on adamantinomatous craniopharyngiomas. We are also considering hiring an AI development team to initiate an AI product focused on:
1. Answering patients' ACP-related diseases questions.
2. Creating a charity platform for pediatric rare diseases.
3. More developments are underway.
Yi retweeted
the redemption arc never gets the same distribution because the villain arc is so satisfying to watch from afar





























